Literature DB >> 20206704

Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease.

Albertine Dubois1, Anne-Sophie Hérard, Benoît Delatour, Philippe Hantraye, Gilles Bonvento, Marc Dhenain, Thierry Delzescaux.   

Abstract

Biomarkers and technologies similar to those used in humans are essential for the follow-up of Alzheimer's disease (AD) animal models, particularly for the clarification of mechanisms and the screening and validation of new candidate treatments. In humans, changes in brain metabolism can be detected by 1-deoxy-2-[(18)F] fluoro-D-glucose PET (FDG-PET) and assessed in a user-independent manner with dedicated software, such as Statistical Parametric Mapping (SPM). FDG-PET can be carried out in small animals, but its resolution is low as compared to the size of rodent brain structures. In mouse models of AD, changes in cerebral glucose utilization are usually detected by [(14)C]-2-deoxyglucose (2DG) autoradiography, but this requires prior manual outlining of regions of interest (ROI) on selected sections. Here, we evaluate the feasibility of applying the SPM method to 3D autoradiographic data sets mapping brain metabolic activity in a transgenic mouse model of AD. We report the preliminary results obtained with 4 APP/PS1 (64+/-1 weeks) and 3 PS1 (65+/-2 weeks) mice. We also describe new procedures for the acquisition and use of "blockface" photographs and provide the first demonstration of their value for the 3D reconstruction and spatial normalization of post mortem mouse brain volumes. Despite this limited sample size, our results appear to be meaningful, consistent, and more comprehensive than findings from previously published studies based on conventional ROI-based methods. The establishment of statistical significance at the voxel level, rather than with a user-defined ROI, makes it possible to detect more reliably subtle differences in geometrically complex regions, such as the hippocampus. Our approach is generic and could be easily applied to other biomarkers and extended to other species and applications. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206704     DOI: 10.1016/j.neuroimage.2010.02.074

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  20 in total

Review 1.  Integrating ADNI results into Alzheimer's disease drug development programs.

Authors:  Jeffrey L Cummings
Journal:  Neurobiol Aging       Date:  2010-05-05       Impact factor: 4.673

2.  Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology.

Authors:  Sonia Do Carmo; Gogce Crynen; Tiffany Paradis; Jon Reed; M Florencia Iulita; Adriana Ducatenzeiler; Fiona Crawford; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2017-05-13       Impact factor: 5.590

3.  PET imaging of the influence of physiological and pathological α-synuclein on dopaminergic and serotonergic neurotransmission in mouse models.

Authors:  Elise Levigoureux; Caroline Bouillot; Thierry Baron; Luc Zimmer; Sophie Lancelot
Journal:  CNS Neurosci Ther       Date:  2018-05-20       Impact factor: 5.243

4.  Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging.

Authors:  Jing Yang; Youssef Zaim Wadghiri; Dung Minh Hoang; Wai Tsui; Yanjie Sun; Erika Chung; Yongsheng Li; Andrew Wang; Mony de Leon; Thomas Wisniewski
Journal:  Neuroimage       Date:  2011-01-19       Impact factor: 6.556

5.  Statistical parametric maps of ¹⁸F-FDG PET and 3-D autoradiography in the rat brain: a cross-validation study.

Authors:  Elena Prieto; María Collantes; Mercedes Delgado; Carlos Juri; Luis García-García; Francisco Molinet; María E Fernández-Valle; Miguel A Pozo; Belén Gago; Josep M Martí-Climent; José A Obeso; Iván Peñuelas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-27       Impact factor: 9.236

6.  Vascular endothelial growth factor associated dissimilar cerebrovascular phenotypes in two different mouse models of Alzheimer's Disease.

Authors:  Nicholas M Tataryn; Vishal Singh; Jonathan P Dyke; Hanna E Berk-Rauch; Dana M Clausen; Eric Aronowitz; Erin H Norris; Sidney Strickland; Hyung Jin Ahn
Journal:  Neurobiol Aging       Date:  2021-07-28       Impact factor: 4.673

7.  Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.

Authors:  Lydie Boussicault; Anne-Sophie Hérard; Noel Calingasan; Fanny Petit; Carole Malgorn; Nicolas Merienne; Caroline Jan; Marie-Claude Gaillard; Rodrigo Lerchundi; Luis F Barros; Carole Escartin; Thierry Delzescaux; Jean Mariani; Philippe Hantraye; M Flint Beal; Emmanuel Brouillet; Céline Véga; Gilles Bonvento
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-18       Impact factor: 6.200

8.  Alzheimer's disease biomarkers in animal models: closing the translational gap.

Authors:  Jonathan J Sabbagh; Jefferson W Kinney; Jeffrey L Cummings
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

9.  Voxel-based analysis of amyloid-burden measured with [(11)C]PiB PET in a double transgenic mouse model of Alzheimer's disease.

Authors:  Boris von Reutern; Barbara Grünecker; Behrooz H Yousefi; Gjermund Henriksen; Michael Czisch; Alexander Drzezga
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

Review 10.  Current technical approaches to brain energy metabolism.

Authors:  L Felipe Barros; Juan P Bolaños; Gilles Bonvento; Anne-Karine Bouzier-Sore; Angus Brown; Johannes Hirrlinger; Sergey Kasparov; Frank Kirchhoff; Anne N Murphy; Luc Pellerin; Michael B Robinson; Bruno Weber
Journal:  Glia       Date:  2017-11-07       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.